Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?
Authors:
- Paul BeinhoffPBPaul Beinhoff
- Lavannya SabharwalLSLavannya Sabharwal
- Vindhya UdhaneVUVindhya Udhane
- Cristina MarantoCMCristina Maranto
- Peter S. LaViolettePLPeter S. LaViolette
- Kenneth M. JacobsohnKJKenneth M. Jacobsohn
- Susan TsaiSTSusan Tsai
- Kenneth A. IczkowskiKIKenneth A. Iczkowski
- Liang WangLWLiang Wang
- William A. HallWHWilliam A. Hall
- Scott M. DehmScott M. Dehm
- Deepak KilariDKDeepak Kilari
Open Access
Abstract
Androgen deprivation therapy (ADT) for metastatic and high-risk prostate cancer (PC) inhibits growth pathways driven by the androgen receptor (AR). Over time, ADT leads to the emergence of lethal castrate-resistant PC (CRPC), which is consistently caused by an acquired ability of tumors to re-activate AR. This has led to the development of second-generation anti-androgens that more effectively antagonize AR, such as enzalutamide (ENZ). However, the resistance of CRPC to ENZ develops rapidly. Studies utilizing preclinical models of PC have established that inhibition of the Jak2-Stat5 signaling leads to extensive PC cell apoptosis and decreased tumor growth. In large clinical cohorts, Jak2-Stat5 activity predicts PC progression and recurrence. Recently, Jak2-Stat5 signaling was demonstrated to induce ENZ-resistant PC growth in preclinical PC models, further emphasizing the importance of Jak2-Stat5 for therapeutic targeting for advanced PC. The discovery of the Jak2V617F somatic mutation in myeloproliferative disorders triggered the rapid development of Jak1/2-specific inhibitors for a variety of myeloproliferative and auto-immune disorders as well as hematological malignancies. Here, we review Jak2 inhibitors targeting the mutated Jak2V617F vs. wild type (WT)-Jak2 that are currently in the development pipeline. Among these 35 compounds with documented Jak2 inhibitory activity, those with potency against WT-Jak2 hold strong potential for advanced PC therapy.Keywords
This publication has 234 references indexed in Scilit:
- Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FBlood Cancer Journal, 2013
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosisLeukemia, 2013
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphomaBlood Cancer Journal, 2011
- Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemiaBlood Cancer Journal, 2011
- Crystal Structures of ABL-Related Gene (ABL2) in Complex with Imatinib, Tozasertib (VX-680), and a Type I Inhibitor of the Triazole Carbothioamide ClassJournal of Medicinal Chemistry, 2011
- The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survivalLeukemia, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinomaBritish Journal of Cancer, 2010
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid TumorsCancer Cell, 2009
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005